ImmuPharma (LON:IMM) Shares Down 7.6% - Here's What Happened

Key Points

• ImmuPharma plc shares fell by 7.6% to GBX 9.98 ($0.14), with trading volume increasing by 201% compared to its average daily volume.
• The company has a market cap of £53.45 million and reported a negative return on equity of 131.41% along with a net margin of 3,519.56%.
• ImmuPharma focuses on developing peptide-based therapeutics for autoimmune diseases, with its lead program being Lupuzor™, aimed at treating lupus and potentially other conditions.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) dropped 7.6% during mid-day trading on Thursday . The stock traded as low as GBX 9.42 ($0.13) and last traded at GBX 9.98 ($0.14). 23,885,457 shares were traded during trading, an increase of 201% from the average daily volume of 7,931,284 shares. The stock had previously closed at GBX 10.80 ($0.15).

ImmuPharma Trading Down 1.0%

The stock has a 50-day moving average price of GBX 2.72 and a two-hundred day moving average price of GBX 2.82. The stock has a market cap of £53.45 million, a price-to-earnings ratio of -1,201.69 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Research analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.